Preferred Label : PD-1 targeted IL-2Rb/g Agonist ANV600;
NCIt synonyms : aIL-2/IL-2 Fusion Protein-Anti-PD-1 Antibody ANV600; Bispecific IL-2Rbeta/gamma Agonist ANV600; Bispecific Antibody ANV600; PD-1 targeted Anti-IL-2 Antibody/IL-2 Fusion Protein ANV600;
NCIt definition : A bispecific antibody composed of a fusion protein comprised of a monoclonal antibody
against the IL-2 receptor subunit alpha (IL2Ra; CD25) binding-site on IL-2 fused to
the cytokine IL-2 and an antibody arm against the human negative immunoregulatory
checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential
immunomodulatory and antineoplastic activities. Upon administration of PD-1 targeted
IL-2Rb/g agonist ANV600, the anti-PD-1 binding moiety targets and binds to PD-1 on
PD-1-postive T-cells within the tumor microenvironment (TME). This allows for the
IL-2 moiety to specifically bind to and activate IL-2Rbeta/gamma on PD-1-positive
T-cells. The selective IL-2Rbeta (CD122)/gamma (CD132) receptor activation promotes
proliferation of neoantigen-specific CD8-positive and PD-1-positive effector T-cells.
This enhances a CTL-mediated immune response against tumor cells and decreases tumor
cell growth. The alphaIL-2 moiety of the anti-IL-2 antibody/IL-2 fusion protein binds
to the IL2Ra binding site on IL-2, thereby preventing the binding of IL-2 to IL2Ra.
Signaling through IL2Ra activates CD4-positive immunosuppressive Tregs, which would
suppress tumor cell killing.;
Molecule name : AN V600; ANV-600;
Origin ID : C211694;
concept_is_in_subset
- has_target
